Aerosol delivery devices Market Size (Value & Volume), Future Potential of Trade 2027
The global Aerosol delivery devices Market is foreseen to expand at a CAGR of 4.9% and reach the valuation of USD 46.72bn in 2027 in comparison to USD 31.46bn in 2019.
Aerosol
drug devices can treat a host of diseases such as lung diseases, pneumonia,
diabetes, asthma, etc. which further drives the global aerosol delivery devices
market during the forecast years.
Researchmoz
elucidates the market in detail including market size, opportunities,
restraints, drivers, and segment domination.
Chronic obstructive pulmonary disease (COPD) to Drive the Market
Chronic obstructive pulmonary disease (COPD) is the most common death-causing disease in the world and drug delivery via inhalation process is the common treatment for COPD. The disease affects nearly 15% of the US population, thus, the increasing prevalence of COPD is projected to drive the global aerosol delivery devices market.
The drug delivery system has had a transformational shift since its inception, from just metered-dose inhalers to handheld inhalers such as dry powder and soft mist inhalers. The growing patient population and growing need for targeted therapies have encouraged a better understanding of the applications of aerosol drug delivery.
Self-administration to Boost the Sales of Aerosol Delivery Devices
The pharmaceutical industry is highly focused on
patient-centricity through bringing in self-administration and giving ease and
real-time experiences to the patients, owing to the expansion of the global
aerosol delivery devices market.
According
to pharma experts, innovations in the field of drug delivery will make
manufacturers and pharma companies, researchers, and scientists to work
together and introduce digitization, leading to the expansion of the global
aerosol delivery devices market.
The
high cost of treatment and side effects of medication might hinder the growth
of the global aerosol delivery devices market to some extent.
However,
the rising geriatric population with severe respiratory diseases such as
asthma, COPD, etc. will drive the global aerosol delivery devices market.
Request A Sample: https://www.researchmoz.us/request-free-sample/?reportid=531
Some of the prominent players in the global aerosol drug delivery market are-
- Koninklijke
Philips N.V.
- 3M
Company
- Aerogen,
INC
- GlaxoSmithKline
Plc (GSK)
- Merck
& co., INC.
- Metall
Zug Group (Clement Clarke International Ltd)
- Merxin
LTD
- Nemera
- Iconovo
AB
- Gerresheimer
AG
- Recipharm
AB (Bespak)
- Johnson
& Johnson (Actelion Pharmaceuticals Ltd)
- Teva
Pharmaceutical Industries Limited
- Vectura
Group PLC
Product Outlook
- Dry
powder inhalers
- Single-dose
inhalers
- Multi-dose
inhalers
- Reservoir
Inhalers
- Metered-dose
inhalers
- Conventional
pressurized inhalers,
- Soft
mist inhalers
- Nebulizers
- Jet
nebulizers
- Ultrasonic
wave nebulizers
- Vibrating
mesh nebulizers
Application Outlook
- Asthma
- Chronic
obstructive pulmonary disease
- Cystic
fibrosis
Non-respiratory diseases
- Diabetes
- Analgesia
- Parkinson’s
disease
Comments
Post a Comment